Key result
Telmisartan is linked to a ~807 mg reduction in 24-hour urinary protein in CKD.
Why the study?
Does telmisartan 40 mg/day improve kidney function and reduce proteinuria in Indian patients with chronic kidney disease?
Observational (n=56)
Does telmisartan 40 mg/day improve kidney function and reduce proteinuria in Indian patients with chronic kidney disease?
p-value: p=<0.05
Telmisartan 40 mg/day significantly improved GFR and reduced proteinuria and blood pressure over 3 months in Indian patients with chronic kidney disease.
May support short-term proteinuria reduction with telmisartan in CKD; leaves open confirmation of renal outcomes in RCTs.
Background: Globally the burden of chronic kidney disease (CKD) is rising, an important cause of death and loss of disability-adjusted life years. Activation of the renin-angiotensin-aldosterone system is involved in its pathogenesis. The aim of the present study was to examine the effects of telmisartan (40 mg/day), an angiotensin receptor blocker (ARB) in Indian patients with CKD in real-life setting.Method: This was a prospective observational study. Fifty-six patients (>18 years) diagnosed with CKD were enrolled into the study. Serum creatinine, 24-h urinary protein, spot urine protein-to-creatinine ratio, glomerular filtration rate (GFR) and blood pressure (BP) were assessed along with safety.Results: A total of 55 patients (96.36% hypertensive; 63.61% diabetic) with mean age of 48.23 years completed the study. At the end of 3 months treatment with telmisartan, 24-h urinary protein, spot urine protein-to-creatinine, serum creatinine and BP significantly reduced (p < .05) by 806.78 mg, 0.95, 0.44 mg/dl and 8.9/4.7 mmHg in the overall population. GFR increased from the baseline value of 52.13 to 65.01 ml/min. Telmisartan was well tolerated and treatment was discontinued in one patient because of hyperkalemia.Conclusion: This study demonstrated that telmisartan effectively and safely reduces proteinuria in chronic kidney disease patients.
No takes yet. Share an insight, caveat, or question.
Agrawal et al. (2016) conducted an observational in chronic kidney disease (n=56). telmisartan was evaluated on 24-h urinary protein, spot urine protein-to-creatinine ratio, serum creatinine, GFR, and blood pressure (p=<0.05). Telmisartan (40 mg/day) significantly reduced 24-h urinary protein by 806.78 mg, serum creatinine by 0.44 mg/dl, and blood pressure by 8.9/4.7 mmHg over 3 months in patients with CKD (p<0.05).